Novanta Inc. (NASDAQ:NOVT) Q3 2024 Results Conference Call November 5, 2024 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair and Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Brian Drab - William Blair Rob Mason - Baird Operator Good morning. My name is Gary, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Incorporated's Third Quarte ...

Novanta (NOVT) came out with quarterly earnings of $0.85 per share, missing the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.85 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.16%. A quarter ago, it was expected that this photonic and motion control components maker would post earnings of $0.69 per share when it actually produced earnings of $0.73, delivering a surprise of 5.80%.Over the last ...

Revenue and Growth - Q3 2024 GAAP revenue of $244 million, a 10.3% increase YoY, driven by acquisitions contributing $21.1 million (9.5%) and favorable foreign exchange impact of $1.8 million (0.8%)[4] - Revenue increased to $244.405 million, up 10.3% from $221.503 million in the previous year[13] - Organic Revenue Growth for Q3 2024 was 10.3%, adjusted for acquisitions and foreign currency effects[21] - Organic revenue growth for 2025 is projected to be up to 10% compared to 2024, driven by new product launches and a recovering investment climate[7] - Medical Solutions segment revenue grew to $103.783 million, up 24.5% from $83.378 million[16] - Robotics and Automation segment revenue increased to $80.027 million, up 19.7% from $66.848 million[16] Profitability and Margins - Q3 2024 GAAP net income of $19 million, down from $21 million in Q3 2023, with diluted EPS at $0.53 compared to $0.59 YoY[4][5] - Q3 2024 adjusted EBITDA of $57 million, up from $52 million in Q3 2023, with adjusted diluted EPS remaining flat at $0.85[5] - Adjusted gross profit margin for Q4 2024 is expected to be approximately 46.0%, with full-year 2024 adjusted gross profit margin at 46.3%[7] - Gross profit margin (GAAP) for Precision Medicine and Manufacturing decreased to 44.6% from 50.8%[17] - Adjusted gross profit margin (Non-GAAP) for Robotics and Automation improved to 52.2% from 50.9%[17] - Operating Income for Q3 2024 was $32.555 million with an Operating Margin of 13.3%[19] - Adjusted Operating Income for Q3 2024 was $46.762 million, with an Adjusted Operating Margin of 19.1%[19] - Adjusted EBITDA for Q3 2024 was $56.976 million, representing an Adjusted EBITDA Margin of 23.3%[21] - Adjusted Net Income for Q3 2024 was $30.645 million, with an Adjusted Diluted EPS of $0.85[19] Cash Flow and Debt - Operating cash flow for Q3 2024 was $23 million, a significant decrease from $44.6 million in Q3 2023[6] - Free Cash Flow for Q3 2024 was $19.465 million, representing 101.4% of Net Income[22] - Net Debt as of September 27, 2024, was $367.637 million[21] - Long-term debt increased to $452.502 million, up 29.5% from $349.404 million[14] - Cash and cash equivalents decreased to $92.690 million, down 11.8% from $105.051 million[14] Guidance and Projections - Q4 2024 revenue guidance of $237 million to $242 million, with adjusted EBITDA expected between $50 million and $52 million, and adjusted diluted EPS between $0.70 and $0.74[7] - Full-year 2024 revenue guidance of $948 million to $953 million, with adjusted EBITDA expected between $208 million and $210 million, and adjusted diluted EPS between $3.02 and $3.06[7] Customer and Product Performance - Customer bookings increased 13% YoY for core businesses, with minimally invasive surgery products achieving a book-to-bill ratio of 1.4[3] - The company's minimally invasive surgery products achieved a book-to-bill ratio of 1.4, indicating strong demand and positive momentum from new product launches[3] Financial Position and Shares - Total assets grew to $1.418823 billion, up 15.7% from $1.226056 billion[14] - Weighted average shares outstanding - Diluted remained stable at 36,129[18] - Weighted average shares outstanding - Diluted for Q3 2023 was 36,041[20] Adjustments and Non-GAAP Metrics - Total non-GAAP adjustments for Q3 2024 amounted to $14.207 million, representing 5.8% of total adjustments[19]

Novanta Inc. (NASDAQ:NOVT) Q2 2024 Results Conference Call August 6, 2024 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair & CEO Robert Buckley - CFO Conference Call Participants Lee Jagoda - CJS Securities Brian Drab - William Blair Rob Mason - Baird Operator Good morning. My name is Dorvin, and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Inc. Second Quarter 2024 Earnings Call. All lines have been placed on ...

Novanta (NOVT) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.69 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 5.80%. A quarter ago, it was expected that this photonic and motion control components maker would post earnings of $0.57 per share when it actually produced earnings of $0.74, delivering a surprise of 29.82%. Over the las ...

Exhibit 99.1 FOR IMMEDIATE RELEASE August 6, 2024 Novanta Announces Financial Results for the Second Quarter 2024 • Second Quarter 2024 GAAP Revenue of $236 million • Second Quarter 2024 GAAP Net Income of $13.8 million • Second Quarter 2024 GAAP Diluted Earnings Per Share of $0.38 • Second Quarter 2024 Adjusted Earnings Per Share of $0.73 • Second Quarter 2024 Adjusted EBITDA of $51 million BEDFORD, Mass., August 6, 2024 -- Novanta Inc. (Nasdaq: NOVT) ("Novanta" or the "Company"), a trusted technology part ...

Novanta is benefiting from strong momentum across medical applications, growing demand for robotics and automation, minimally invasive and robotic surgery and precision medicine. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements. The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's ...

Investors might want to bet on Novanta (NOVT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a chang ...

Conference Call Participants Novanta Inc. (NASDAQ:NOVT) Q1 2024 Earnings Conference Call May 7, 2024 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair & CEO Robert Buckley - CFO Lee Jagoda - CJS Securities Brian Drab - William Blair Rob Mason - Baird Operator Good morning. My name is Gary and I will be your conference operator today. At this time, I would like to welcome everyone to Novanta Inc. First Quarter 2024 Earnings Call. All lines have been placed on mute ...

Novanta (NOVT) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 29.82%. A quarter ago, it was expected that this photonic and motion control components maker would post earnings of $0.63 per share when it actually produced earnings of $0.63, delivering no surprise.Over the last four qu ...